Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis.
The purpose of the study was to analyze the relationship between the serum concentration of soluble tumour necrosis factor-alpha type 1 (sTNF-R1), the severity of plaque-type psoriasis and therapeutic response. We compared sTNF-R1 in 25 patients treated with narrowband ultraviolet B (NB-UVB) radiation and 25 patients treated with systemic photochemotherapy (psoralen plus UVA-PUVA). The pretreatment Psoriasis Area and Severity Index (PASI) score and sTNF-R1 concentration were 16.32+/-5.26 and 1.99+/-0.40 ng ml(-1), respectively, in the group treated with NB-UVB, and 17.22+/-3.48 and 2.07+/-0.31 ng ml(-1), respectively, in the group treated with PUVA. The concentration of sTNF-R1 in healthy controls was 1.49+/-0.34 ng ml(-1) (p<0.05 compared with patients with psoriasis). The pretreatment PASI score correlated with sTNF-R1 in both treatment groups (r=0.46 and r=0.44, p<0.05). NB-UVB and PUVA gave similar therapeutic effects (the PASI score after 20 treatments was 4.42+/-1.67 in the NB-UVB-treated group and 5.55+/-2.10 in PUVA-treated patients); however, the sTNF-R1 concentration at the same time differed significantly: 1.52+/-0.37 ng ml(-1) and 1.98+/-0.39 ng ml(-1) (p<0.001), respectively. Moreover, the decline in sTNF-R1 in both treatment groups was significant only in patients in whom the duration of skin lesions was less than 3 months. The results suggest that the value of serum sTNF-R1 concentration as a marker of response to phototherapy may depend on duration of skin lesions and the treatment method.
Serwin
Agnieszka B
AB
Department of Dermatology and Venereology, Medical University of Bialystok 14, Zurawia St. 15-540 Bialystok, Poland. agabser@amb.edu.pl
Chodynicka
Bozena
B
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015536:Down-Regulation; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000627:therapeutic use*; D008875:Middle Aged; D011701:PUVA Therapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014467:Ultraviolet Therapy
D015415:Biomarkers; D017319:Photosensitizing Agents; D047888:Receptors, Tumor Necrosis Factor, Type I; D008730:Methoxsalen